Diego A. Garcia-Diaz

Av. San Fernando #22
Tlalpan, DIF 14080, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis.

Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis.

Journal: Journal of chemotherapy (Florence, Italy)

Published: February 23, 2026

Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.

Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.

Journal: BMC cancer

Published: October 26, 2025

Stage I Non-Seminomatous Testicular Cancer: Long-Term Follow-Up with Surveillance Approach Post-Orchiectomy.

Stage I Non-Seminomatous Testicular Cancer: Long-Term Follow-Up with Surveillance Approach Post-Orchiectomy.

Journal: Oncology

Published: July 02, 2024

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: December 05, 2022

Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.

Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.

Journal: Cancer biomarkers : section A of Disease markers

Published: May 31, 2021

Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.

Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.

Journal: Oncology

Published: October 13, 2020

Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.

Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 08, 2020

Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.

Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 29, 2020

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: April 10, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026